This is a meaningful regulatory catalyst that opens a new commercial market and provides a pathway to additional jurisdictions via the Free Sale Certificate. Watch for initial sales traction in Israel and progress toward CE Mark by year-end 2026, which would unlock the EU market. The stock has a history of negative drift on prior neutral-to-bullish filings, so consider taking partial profits on any initial pop.
Price Chart
Executive Summary
Microbot Medical announced it received regulatory approval from the Israeli Ministry of Health's AMAR Division to market and commercialize the LIBERTY Endovascular Robotic System in Israel. This is the first international regulatory clearance for the system outside the U.S. and enables the company to obtain a Free Sale Certificate to support submissions in additional jurisdictions. The company also noted it is working toward CE Mark certification by end of 2026 for EU market expansion.
Key Facts
- Received AMAR regulatory approval from Israeli Ministry of Health for LIBERTY Endovascular Robotic System
- Israel is the second jurisdiction and first outside the U.S. to grant marketing clearance
- Approval enables obtaining a Free Sale Certificate to support submissions in additional jurisdictions
- Company pursuing CE Mark certification, targeting completion by end of 2026 for EU expansion
- Multiple U.S. accounts in Georgia, Florida, New York, Massachusetts, Michigan, and North Carolina have already adopted the LIBERTY System
Financial Impact
No financial figures provided in the filing; revenue impact depends on commercialization ramp in Israel and subsequent jurisdictions.
Risk Factors
- Commercialization in Israel may be slower than expected; no revenue guidance provided
- CE Mark certification timeline could slip beyond end of 2026
- Geopolitical risks in Israel could disrupt operations or market access
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025171 |
| Exhibit: ex99-1.htm | 0001493152-26-025171 |
| Document: 0001493152-26-025171-index-headers.html | 0001493152-26-025171 |
| Document: 0001493152-26-025171-index.html | 0001493152-26-025171 |
| Document: 0001493152-26-025171.txt | 0001493152-26-025171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.9799 | awaiting T+1 | — | $0.9826 (+0.28%) |
Oct 20, 2026 6d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9826 (+3.70%) |
Oct 6, 2026 20d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9826 (−8.17%) |
Oct 6, 2026 20d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9826 (−8.17%) |
Sep 28, 2026 28d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9826 (−21.39%) |
Aug 11, 2026 10w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9826 (−41.51%) |
Jul 21, 2026 13w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9826 (−45.41%) |
Jul 7, 2026 15w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9826 (−48.28%) |
Jun 30, 2026 16w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9826 (−49.61%) |
Jun 16, 2026 18w ago | 8-K | $1.82 $1.88 | ▲ +3.30% | ▲ +4.55% | $0.9826 (−46.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers